Syndax Pharmaceuticals Inc
Business
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company developing innovative cancer therapies. The company has two FDA-approved medicines: Revuforj (revumenib), a first-in-class menin inhibitor for relapsed/refractory acute leukemia, and Niktimvo (axatilimab-csfr), a first-in-class CSF-1R-blocking antibody for chronic graft-versus-host disease. Syndax is advancing clinical development programs in acute leukemia, myelofibrosis, and idiopathic pulmonary fibrosis, with commercialization in the United States and partnerships for development and geographic expansion.
Summary from 10-K filed 2026-02-26
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | 172 | 24 | 0 | 0 | 140 | |
| Cost of product sales | 7 | 826,000 | 0 | — | — | |
| Research and development expenses | 259 | 242 | 163 | 118 | 88 | |
| Selling, general and administrative | 180 | 121 | 67 | 33 | 25 | |
| Total operating expenses | 445 | 363 | 230 | 152 | 113 | |
| Loss from operations | −273 | −340 | −230 | −152 | 26 | |
| Royalty interest expense | −34 | −5 | 0 | — | — | |
| Other interest (expense) income | −6,000 | 1,000 | −208,000 | −3 | — | |
| Interest income | 23 | 26 | 21 | 6 | 403,000 | |
| Other expense, net | −1 | −247,000 | −361,000 | −316,000 | 202,000 | |
| Total other income | −12 | 21 | 21 | 2 | −1 | |
| Net income | −285 | −319 | −209 | −149 | 25 | |
| Net loss attributable to common stockholders | −285 | −319 | −209 | −149 | 25 | |
| Basic loss per share attributable to common stockholders | −3.29 | −3.72 | −2.98 | −2.46 | 0.48 | |
| Diluted loss per share attributable to common stockholders | −3.29 | −3.72 | −2.98 | −2.46 | 0.46 | |
| Basic loss per share attributable to common stockholders (shares) | 87 | 86 | 70 | 61 | 52 | |
| Diluted loss per share attributable to common stockholders (shares) | 87 | 86 | 70 | 61 | 54 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2024 2024-10-31 | FY 2024 2024-04-30 | FY 2023 2023-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 135 | 154 | — | — | 295 | |
| Short-term investments | 259 | 419 | — | — | 275 | |
| Accounts receivable, net | 38 | 8 | — | — | 0 | |
| Inventory, net | 33 | 366,000 | — | — | 0 | |
| Short-term deposits | 20 | 10 | — | — | 7 | |
| Other receivables, net | 6 | 4 | — | 4 | 0 | |
| Collaboration receivable, net | 24 | 0 | — | — | — | |
| Prepaid expenses and other current assets | 13 | 9 | — | — | 3 | |
| Total current assets | 528 | 603 | — | — | 581 | |
| Long-Term Investments | 0 | 120 | — | — | 30 | |
| Property and equipment, net | 181,000 | 0 | — | — | 8,000 | |
| Right-of-use asset | 1 | 2 | 2 | — | 1 | |
| Restricted cash | 102,000 | 217,000 | — | — | 217,000 | |
| Total assets | 530 | 725 | — | — | 613 | |
| Accounts payable | 17 | 12 | — | — | 10 | |
| Collaboration payable, net | 0 | 19 | — | — | 7 | |
| Accrued expenses and other current liabilities | 103 | 60 | — | — | 40 | |
| Current portion of royalty interest financing | 0 | 12 | — | — | 0 | |
| Current portion of right-of-use liability | 470,000 | 471,000 | — | — | 1 | |
| Current Portion Of Capital Lease | 2,000 | 9,000 | — | — | 12,000 | |
| Total current liabilities | 120 | 104 | — | — | 58 | |
| Royalty interest financing, less current portion | 344 | 332 | — | — | — | |
| Right-of-use liability, less current portion | 1 | 2 | — | — | 10,000 | |
| Total long-term liabilities | 345 | 333 | — | — | 588,000 | |
| Total liabilities | 465 | 437 | — | — | 59 | |
| Commitments and contingencies (Note 18) | — | — | — | — | — | |
| Preferred stock, $0.001 par value, 10,000,000 shares authorized; 0 shares outstanding at December 31, 2025 and December 31, 2024 | 0 | 0 | — | — | 0 | |
| Common stock, $0.0001 par value, 200,000,000 shares authorized at December 31, 2025 and December 31, 2024, respectively; 87,405,979 and 85,694,443 shares outstanding at December 31, 2025 and December 31, 2024, respectively | 9,000 | 9,000 | — | — | 8,000 | |
| Additional paid-in capital | 1,571 | 1,509 | — | — | 1,456 | |
| Accumulated other comprehensive income | 452,000 | 163,000 | — | — | 218,000 | |
| Accumulated deficit | −1,507 | −1,221 | — | — | −902 | |
| Total stockholders' equity | 65 | 288 | — | — | 554 | |
| Total liabilities and stockholders' equity | 530 | 725 | — | — | 613 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Net loss | −285 | −319 | −209 | −149 | 25 | |
| Depreciation | 6,000 | 8,000 | 12,000 | 33,000 | 43,000 | |
| Accretion of investments | −11 | −13 | −15 | −3 | 644,000 | |
| Non-cash operating lease expense | 946,000 | 989,000 | 739,000 | 421,000 | 413,000 | |
| Stock-based compensation | 48 | 43 | 31 | 16 | 13 | |
| Amortization of debt issuance costs | 228,000 | 30,000 | 0 | 0 | — | |
| Provision for credit losses | 4 | 0 | 0 | — | — | |
| Inventory reserves | 163,000 | 0 | 0 | — | — | |
| Accounts receivable | −30 | −8 | 0 | 0 | — | |
| Inventory | −32 | −366,000 | 0 | 0 | — | |
| Prepaid expenses and other current assets | −15 | −8 | 676,000 | −3 | −1 | |
| Collaboration (payable) receivable, net | −43 | 12 | 11 | −3 | 0 | |
| Other receivable | −6 | −4 | 0 | 0 | — | |
| Other assets | 0 | 463,000 | 0 | — | — | |
| Accounts payable | 5 | 2 | 6 | −1 | 2 | |
| Accrued expenses and other current liabilities | 42 | 19 | 15 | 9 | 3 | |
| Net cash used in operating activities | −323 | −275 | −161 | −134 | 29 | |
| Purchases of property and equipment | −187,000 | 0 | 0 | 0 | −129,000 | |
| Purchases of short and long-term investments | −196 | −557 | −355 | −495 | −295 | |
| Proceeds from maturities of short-term investments | 486 | 337 | 472 | 309 | 254 | |
| Net cash provided by (used in) investing activities | 290 | −220 | 118 | −186 | −41 | |
| Proceeds from Purchase and Sale agreement, net | 0 | 344 | 0 | 0 | — | |
| Proceeds from ESPP | 2 | 2 | 910,000 | 401,000 | 367,000 | |
| Proceeds from stock option exercises | 12 | 8 | 5 | 12 | 6 | |
| Net cash provided by financing activities | 14 | 353 | 264 | 172 | 118 | |
| NET (DECREASE) INCREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH | −19 | −141 | 221 | −148 | 107 | |
| Issuance costs in accounts payable and accrued expenses | 0 | 0 | 250,000 | 131,000 | — | |
| Lease assets recognized upon lease remeasurement | 0 | 2 | 0 | 0 | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Syndax Pharmaceuticals Inc's CIK number?
Syndax Pharmaceuticals Inc's SEC CIK number is 0001395937 (1395937). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Syndax Pharmaceuticals Inc's SEC filings?
All of Syndax Pharmaceuticals Inc's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Syndax Pharmaceuticals Inc last report earnings?
Syndax Pharmaceuticals Inc (SNDX) most recently filed an earnings 8-K with the SEC on Apr 30, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-197124). This is Syndax Pharmaceuticals Inc's most recent earnings filing of record — not a forecast of its next earnings date.
What is Syndax Pharmaceuticals Inc's most recent earnings 8-K?
Syndax Pharmaceuticals Inc's latest earnings 8-K (Item 2.02) was filed Apr 30, 2026 under accession 0001193125-26-197124. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Syndax Pharmaceuticals Inc's latest earnings 8-K →
Look up any company's CIK number →